500 episodes
Citeline Podcasts Citeline
-
- Business
-
-
4.3 • 26 Ratings
-
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
-
Scrip's Five Must-Know Things - 30 April 2024
Audio roundup of selected biopharma industry content from Scrip over the business week ended 26 April 2024. In this episode: 2023’s top selling drugs and the COVID cliff; falling sales force Roche to reassess priorities; Phase III immunology win for Sanofi; BMS’s strong pipeline: and which companies could be acquired next.
https://scrip.citeline.com/SC150182/Quick-Listen-Scrips-Five-MustKnow-Things -
2024 Global Generics & Biosimilars Awards
2024 Global Generics & Biosimilars Awards by Citeline
-
Podcast: Facilitating Patient Monitoring in CAR-T Development
Learn how molecular technology is enhancing patient safety for CAR-T clinical trials.
US FDA recently initiated class safety labeling changes after evaluating the safety of CAR-T cancer treatment therapies. What does this mean for developers in the CAR-T landscape? Listen to your free podcast to find out.
Listen in on the conversation as experts from Cerba discuss facilitating patient safety measures in CAR-T therapies by accurately identifying the integration of viral vectors, utilizing flow cytometry, and more.
Listen now as experts discuss answers to:
· What patient monitoring is required by the FDA?
· What molecular technology does Cerba use and how does it meet FDA requirements?
· What is the importance of cytometry assays in monitoring CAR-T cells?
· What are the opportunities for combining flow cytometry with genomic solutions?
· What key innovations are poised to improve patient monitoring in clinical trials? -
Drug Fix: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics
Pink Sheet reporter and editors discuss the impact of FDA biosimilar promotion guidance on the future of the interchangeability designation (:34), upcoming guidance on accelerated approval for gene therapies (14:15), and partisan attacks on the agency from Capitol Hill (27:13).
More On These Topics From The Pink Sheet
Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says: https://pink.citeline.com/PS150143/Rx-Advertising-Interchangeability-Doesnt-Mean-Clinical-Superiority-To-Other-Biosimilars-FDA-Says
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios: https://pink.citeline.com/PS150140/US-FDA-Gene-Therapy-Accelerated-Approval-Guidance-Will-Describe-Buckets-Of-Use-Scenarios
Partisan Politics Returns To US FDA Congressional Oversight: https://pink.citeline.com/PS150114/Partisan-Politics-Returns-To-US-FDA-Congressional-Oversight -
Dr. Xue Discusses Treatment Guideline Updates for COPD in This Q&A Session
Pulmonologist Bing Xue, MD, reviews the latest GOLD guidelines and discusses relevant topics regarding COPD treatment.
-
China Biotech Podcast - 26 April 2024 (Chinese and English Language)
Join Scrip's China-based editors Brian Yang and Dexter Yan in this Chinese/English podcast as they look at data presented to AACR by Chinese pharma firms and recent acquisitions of China-based companies. UK-based writer Andrew McConaghie also joins to provide his perspectives, including on the proposed US BIOSECURE Act.
https://scrip.citeline.com/SC150164/China-Biotech-Podcast-AACR-BIOSECURE-European-Perspectives
Customer Reviews
My Top Source for Industry News
I use all of Informa's sources of information, but in a busy world, the podcasts keep me most updated on the issues that affect my work as a healthcare consultant. I can't keep on top of everything, but with my podcasts loaded up, I can hear great analysis on what's most relevant today while running or doing chores around the house.
Too many “uh” during the conversation
Too many “uh” and broken sentences. I find it so painful to follow
Good information, bad delivery
Often times a podcast with very good information, but quite poorly delivered. As someone who regularly conducts market research interviews via telephone and web, I’m very familiar with reading through far too many colloquialisms, filler words, and trite expressions. Words and phrases such as “right “and you know” “um” “and” “uh” make it painful to listen to in any regular basis.